What it does
Key investments include Kirkstall, UV light detection group Paraytec, propeller and rotating shaft monitoring group Gyrometric Systems, microscope imaging firm PhaseFocus and Sentinel Medical, a spin-out of Paraytec developing technology to detect cancer cells in urine.
The company also has a 51.72% stake in Pharm2Farm Limited (P2F), a plant nutrients specialist.
How it is doing
A new antiviral face mask that can kill COVID-19 will go on sale by the end of the year.
This follows a flurry of activity at Braveheart investee company Pharm2Farm (P2F), which has developed a textile coating incorporating nanoparticles with long-lasting virucidal properties.
It now has testing results from two independent labs that show the mask textile has a ‘kill rate’ of over 90% for up to seven hours, meeting the requirements for ISO 18184 certification.
Meanwhile, Paraytec Limited has completed proof of concept trials for a coronavirus test it is developing with the University of Sheffield.
Following the achievement of proof of concept for the optical detection system on October 5, the focus has been on the proof of concept trials for the capture and signal generation modules for the test.
What the boss says: Trevor Brown, chief executive
"This is a phenomenal achievement for all concerned. The inspirational leadership and innovative brilliance of Professor Carl Smythe and his talented team have resulted in proof of concept in a little over four months," he commented on Paraytec's update.